Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib for active discoid and/or subacute cutaneous lupus erythematosus
2023-504161-22-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in cutaneous lupus erythematosus (CLE), discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: Percentage change from baseline in CLASI-A score. Planned start Jun 2021; status: authorised.
02
Drugs
deucravacitinib
03
Conditions
cutaneous lupus erythematosus (CLE)discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on 2023-504161-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504161-22-00.